Aslan applied for the Taipei Exchange (TPEx) listing with Qualified Technology Enterprise (QTE) status, with a paid-in capital of NT$1,157 million (US$36.5 million).
Dr Carl Firth is Chairman of ASLAN Pharmaceuticals. The Company is represented by legal firm K&L Gates and has appointed KGI Securities as the lead underwriter.
ASLAN Pharmaceuticals is led by a highly experienced management team with global pharmaceutical expertise. It is a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types.
ASLAN is headquartered in Singapore, with a platform that reaches across the region via its offices in Taiwan, China and Australia.
This enables the company to conduct and support regional clinical development programmes.
It is developing five drugs addressing multiple indications, including biliary tract cancer, gastric cancer and breast cancer.
ASLAN has several compounds in late stage development. One is varlitnib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer and is entering pivotal studies for biliary tract cancer.
The other is ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer.
